Journal of Clinical Endocrinology & Metabolism, Vol 59, 908-915, Copyright © 1984 by Endocrine Society

ARTICLES

Immunoassay of a somatomedin-binding protein from human amniotic fluid: levels in fetal, neonatal, and adult sera

SL Drop, DJ Kortleve, HJ Guyda and BI Posner

We developed a specific RIA for a somatomedin (Sm)-binding protein, with an approximate mol wt of 35-40,000, purified from midgestational human amniotic fluid (AF) and termed AF-binding protein (AFBP). After Sephadex G-200 chromatography AFBP-RIA activity was found in fractions of fetal and cord serum only at a kav corresponding to a mol wt of +/- 40,000. Whole serum or plasma dilutions in a range of 1:20 to 1:600 showed parallelism with the standard curve. Sm-binding activity in fetal serum was found solely at a mol wt of 30-40,000; in cord serum additionally at a mol wt range of 150-200,000. AFBP serum or plasma concentrations determined by RIA were influenced by several factors: AFBP values in eight adults were highest in the morning (mean +/- SEM, 0.7 +/- 0.1 mu geq/ml) and lowest at night (0.3 +/- 0.1). AFBP values in pre- and postnatal serum showed a gradual decline with increasing age: fetal serum: mean +/- SEM, 36.7 +/- 15.7 (n = 17); adults: 0.6 +/- 0.07 mu geq/ml (n = 19). In serum from GH-deficient children AFBP concentrations were significantly higher than in an age-matched control group (P less than 0.05). Elevated values also were found in serum of children with end-stage renal failure and in serum of pregnant women at 36 weeks of gestation. AFBP was found in urine of preterm infants (mean +/- SEM, 0.04 +/- 0.005 mu geq/ml; n = 31). AFBP immunoreactivity was demonstrable in serum of three orangoutan mothers and their three children and in medium of a hepatoma cell line (PLC/PRF/5) but not in bovine, porcine, rabbit, or rat serum or in medium of cell cultures of (pre-)term placentae. We conclude that AFBP immunoreactivity is present in pre- and postnatal serum and has striking similarity to an unsaturated serum Sm-binding protein with a mol wt of +/- 40,000.

This article has been cited by other articles:

				V. Cingel-Ristic, J. W. van Neck, J. Frystyk, S. L. S. Drop, and A. Flyvbjerg Administration of Human Insulin-Like Growth Factor-Binding Protein-1 Increases Circulating Levels of Growth Hormone in Mice Endocrinology, September 1, 2004; 145(9): 4401 - 4407. [Abstract] [Full Text] [PDF]

				M. Westwood, J.M. Gibson, S. R. Sooranna, S. Ward, J. P. Neilson, and R. Bajoria Genes or placenta as modulator of fetal growth: evidence from the insulin-like growth factor axis in twins with discordant growth Mol. Hum. Reprod., April 1, 2001; 7(4): 387 - 395. [Abstract] [Full Text] [PDF]

				J.M. Gibson, J.D. Aplin, A. White, and M. Westwood Regulation of IGF bioavailability in pregnancy Mol. Hum. Reprod., January 1, 2001; 7(1): 79 - 87. [Abstract] [Full Text] [PDF]

				N. A. Martina, E. Kim, U. Chitkara, N. C. Wathen, T. Chard, and L. C. Giudice Gestational Age-Dependent Expression of Insulin-Like Growth Factor-Binding Protein-1 (IGFBP-1) Phosphoisoforms in Human Extraembryonic Cavities, Maternal Serum, and Decidua Suggests Decidua as the Primary Source of IGFBP-1 in these Fluids during Early Pregnancy J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1894 - 1898. [Abstract] [Full Text] [PDF]